Light Street Capital Management LLC Sells 230,000 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Light Street Capital Management LLC lessened its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 28.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 578,235 shares of the company’s stock after selling 230,000 shares during the period. Cellebrite DI accounts for approximately 2.3% of Light Street Capital Management LLC’s holdings, making the stock its 17th biggest position. Light Street Capital Management LLC owned about 0.28% of Cellebrite DI worth $12,739,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Gen Wealth Partners Inc bought a new stake in Cellebrite DI during the 4th quarter valued at approximately $85,000. NewEdge Advisors LLC increased its holdings in Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after acquiring an additional 3,352 shares during the last quarter. R Squared Ltd purchased a new stake in Cellebrite DI in the 4th quarter worth $100,000. Polen Capital Management LLC purchased a new position in shares of Cellebrite DI during the fourth quarter valued at about $222,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Cellebrite DI in the fourth quarter worth about $234,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Trading Up 2.9%

Shares of Cellebrite DI stock opened at $19.83 on Monday. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The stock’s fifty day moving average price is $18.92 and its 200-day moving average price is $20.25. The firm has a market cap of $4.75 billion, a P/E ratio of -14.27, a P/E/G ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on CLBT shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.